161 related articles for article (PubMed ID: 20797437)
1. Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration.
Depreter F; Amighi K
Eur J Pharm Biopharm; 2010 Nov; 76(3):454-63. PubMed ID: 20797437
[TBL] [Abstract][Full Text] [Related]
2. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method.
You Y; Zhao M; Liu G; Tang X
J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186
[TBL] [Abstract][Full Text] [Related]
3. Insulin-micro- and nanoparticles for pulmonary delivery.
Klingler C; Müller BW; Steckel H
Int J Pharm; 2009 Jul; 377(1-2):173-9. PubMed ID: 19446621
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
Pilcer G; Vanderbist F; Amighi K
Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
Razavi Rohani SS; Abnous K; Tafaghodi M
Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
[TBL] [Abstract][Full Text] [Related]
6. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery.
Zhang Y; Zhu J; Tang Y; Chen X; Yang Y
Drug Dev Ind Pharm; 2009 Sep; 35(9):1059-65. PubMed ID: 19640250
[TBL] [Abstract][Full Text] [Related]
7. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
8. Development of inhalable dry powder formulation of basic fibroblast growth factor.
Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
[TBL] [Abstract][Full Text] [Related]
9. Fabrication of inhalable spore like pharmaceutical particles for deep lung deposition.
Shen ZG; Chen WH; Jugade N; Gao LY; Glover W; Shen JY; Yun J; Chen JF
Int J Pharm; 2012 Jul; 430(1-2):98-103. PubMed ID: 22486960
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice.
Duret C; Wauthoz N; Merlos R; Goole J; Maris C; Roland I; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2012 Aug; 81(3):627-34. PubMed ID: 22538097
[TBL] [Abstract][Full Text] [Related]
11. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
12. Microencapsulated chitosan nanoparticles for lung protein delivery.
Grenha A; Seijo B; Remuñán-López C
Eur J Pharm Sci; 2005; 25(4-5):427-37. PubMed ID: 15893461
[TBL] [Abstract][Full Text] [Related]
13. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs.
Ungaro F; d'Emmanuele di Villa Bianca R; Giovino C; Miro A; Sorrentino R; Quaglia F; La Rotonda MI
J Control Release; 2009 Apr; 135(1):25-34. PubMed ID: 19154761
[TBL] [Abstract][Full Text] [Related]
14. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
15. Design of spray dried insulin microparticles to bypass deposition in the extrathoracic region and maximize total lung dose.
Ung KT; Rao N; Weers JG; Huang D; Chan HK
Int J Pharm; 2016 Sep; 511(2):1070-9. PubMed ID: 27480399
[TBL] [Abstract][Full Text] [Related]
16. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
17. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
[TBL] [Abstract][Full Text] [Related]
18. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations.
Hassan A; Farkas D; Longest W; Hindle M
Int J Pharm; 2020 Dec; 591():120027. PubMed ID: 33130220
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a new inhalable thymopentin formulation.
Wang L; Zhang Y; Tang X
Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
[TBL] [Abstract][Full Text] [Related]
20. The effect of operating and formulation variables on the morphology of spray-dried protein particles.
Maa YF; Costantino HR; Nguyen PA; Hsu CC
Pharm Dev Technol; 1997 Aug; 2(3):213-23. PubMed ID: 9552449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
